同步放化疗治疗中晚期宫颈癌的疗效分析

Clinical analysis of concurrent chemotherapy plus radiotherapy for advanced cervical cancer

目的:评价同步放化疗治疗中晚期宫颈癌的疗效。方法:将中晚期宫颈癌患者161例随机分为两组:同步放化疗组81例,采用紫杉醇+顺铂周疗,同时行根治性放疗,体外放疗+192Ir腔内放疗。单纯放疗组80例行根治性放疗,放疗方法同同步放化疗组。结果:同步放化疗组与单纯放疗组有效率分别为87.65%和56.25%,两组差异有统计学意义,P<0.05。同步放化疗组与单纯放疗组的3年生存率分别为75.3%和57.5%,差异有统计学意义,P<0.05。同步放化疗组骨髓抑制及消化道反应发生率均高于单纯放疗组,P<0.05。及时对症治疗后,患者均可耐受。远期直肠膀胱并发症未见增加。结论:同步放化疗治疗中晚期宫颈癌可提高近期疗效及3年生存率。

OBJECTIVE： To assess the effect of concurrent chemotherapy plus radiotherapy for advanced cervical cancer. METHODS..A total of 161 patients with advanced cervical cancer were randomized into two groups： 81 of concurrent radiotherapy plus chemotherapy and 80 of radiotherapy alone. The concurrent radiotherapy plus chemotherapy group were transfused with Paclitaxel and DDP, and the two groups were received radical radiotherapy with the same way. RESULTS： In the group of concurrent radiotherapy plus chemotherapy, the response rate was 87.65% and the 3-year survival rate was 75.3%. In the group of radiotherapy alone, the response rate was 56. 25% and the 3 year survival rate was 57.5 %. There was a significant difference setween the two groups （P〈0.05）. More serious toxicity was found in the group of concurrent radiotherapy plus chemotherapy（P〈0.05）, but it was tolerable. CONCLUSION： Concurrent chemoradiotherapy for advanced cervical cancer can significantly improve the response rate and 3-year survival rate.